Results 31 to 40 of about 12,780 (188)

folliculitis and a systematic review of treatments

open access: yes, 2020
Folliculitis is an inflammatory process involving the hair follicle, frequently attributed to infectious causes. Malassezia, an established symbiotic yeast that can evolve to a skin pathogen with opportunistic attributes, is a common source of ...
Henning, M. A. S.   +11 more
core   +1 more source

Squamous cell carcinoma originating in folliculitis decalvans [PDF]

open access: yes
Folliculitis decalvans is a chronic and progressive scarring alopecia at the vertex and occipital scalp with a predilection for middle-aged men. Squamous cell carcinoma is an exceedingly rare complication of folliculitis decalvans, reported in 5 cases ...
Fraga, Garth   +5 more
core   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week, double‐blind, placebo‐controlled, phase 3 Program for Evaluation
Philip J. Mease   +20 more
wiley   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu   +7 more
wiley   +1 more source

Tofacitinib Regulates β‐Catenin Nuclear Translocation to Inhibit FLS Migration and Alleviate Clinical Symptoms of RA

open access: yesiNew Medicine, EarlyView.
ABSTRACT Objective Tofacitinib is a Janus kinase (JAK) inhibitor approved for the treatment of moderate‐to‐severe rheumatoid arthritis (RA). However, its synovium‐related molecular mechanisms, particularly its regulatory effect on fibroblast‐like synoviocyte (FLS) migration, remain incompletely understood.
Shuqi Fang   +13 more
wiley   +1 more source

Artificial intelligence-based prescription of personalized scalp cosmetics improved the scalp condition: efficacy results from 100 participants

open access: yesJournal of Dermatological Treatment
Background: Scalp-related symptoms such as dandruff and itching are common with diverse underlying etiologies. We previously proposed a novel classification and scoring system for scalp conditions, called the scalp photographic index (SPI); it grades ...
Bo Ri Kim   +10 more
doaj   +1 more source

A Case Report of Necrotizing Eosinophilic Folliculitis Occurring After Rhus Ingestion

open access: yesClinical, Cosmetic and Investigational Dermatology, 2022
En Hyung Kim,1 Dae Hwi Eun,2 Ji Yeoun Lee2 1Department of Dermatology, Bundang Jesaeng General Hospital, Seongnam, Gyeonggi, Korea; 2Department of Dermatology, College of Medicine, Chungbuk National University, Cheongju, KoreaCorrespondence: Ji Yeoun Lee,
Kim EH, Eun DH, Lee JY
doaj  

Clinico-pathological concordance rate of scalp lesions showing alopecia

open access: yesIndian Journal of Dermatology, 2022
Background: Some alopecic diseases can be diagnosed by detailed history taking and physical examination, but in many cases, biopsy must be performed to make a definite diagnosis.
Soo Hyun Jeong   +4 more
doaj   +1 more source

Differential Diagnosis of the Scalp Hair Folliculitis [PDF]

open access: yes, 2011
Folikulitis vlasišta je relativno česta pojava u dermatološkoj praksi koja zbog nedostatka jasnih smjernica predstavlja značajan dijagnostički i terapijski izazov.
Bradić, Lada   +6 more
core  

Real‐World Effectiveness and Safety of Topical Ruxolitinib in Adolescents With Vitiligo: A 52‐Week Retrospective Study

open access: yesJEADV Clinical Practice, EarlyView.
Topical ruxolitinib 1.5% cream was assessed in 39 adolescents with non‐segmental vitiligo. Median T‐VASI fell at week 24 (n = 34) and week 52 (n = 18), with repigmentation most pronounced on the face: 55.6% reached F‐VASI50 at week 52. Few adverse events were recorded, all mild application‐site reactions in 4 of 39 patients.
L. Coronella   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy